A Protocol to Switch High-Dose, Methadone-Maintained Subjects to Buprenorphine

References

• Jasinski D R, Pevnick J S, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 1978; 35: 501–516
   PubMed Web of Science ®Google Scholar
• San L, Cami J, Fernandez T. Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. Br J Addict 1992; 87: 55–62
   PubMedGoogle Scholar
• O'Connor J J, Moloney E, Travers R. Buprenorphine abuse among opiate addicts. Br J Addict 1988; 83: 1085–1087
   PubMedGoogle Scholar
• Mello N K, Lukas S E, Bree MP. Progressive ratio performance maintained by buprenorphine, heroin, and methadone in macaque monkeys. Drug Alcohol Depend 1988; 21: 81–97
   Google Scholar
• Lukas S E, Brady J V, Griffiths RR. Comparison of opioid self-injection and disruption of schedule-controlled performance in the baboon. J Pharmacol Exp Ther 1986; 238: 924–931
   Google Scholar
• Mello N K, Mendelson JH. Behavioral pharmacology of buprenorphine, in Mixed agonist-antagonist analgesics. Edited by Schuster CR, Harris LS. Drug Alcohol Depend 1985; 14: 283–303
   Google Scholar
• Jasinski D R, Henningfield J E, Hickey JE. Progress report of the NIDA Addiction Research Center. National Institute on Drug Abuse Research, Baltimore, MD 1982; 92–98, Monograph 43. Rockville, MD, 1983
   Google Scholar
• Fudala P J, Jaffe J H, Dax EM. Use of buprenorphine in the treatment of opioid addiction II: physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47: 525–534
   PubMed Web of Science ®Google Scholar
• Foltin R W, Fischman MW. Interaction of buprenorphine with cocaine-morphine combinations. Exp Clin Pharmacol 1995; 3: 261–269
   Google Scholar
• Foltin R W, Fischman MW. Effects of buprenorphine on the self-administration of cocaine by humans. Behavioral Pharmacology 1994; 5: 79–89
   Google Scholar
• Kosten T R, Kleber H D, Morgan C. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry 1989; 26: 637–639
   PubMed Web of Science ®Google Scholar
• Johnson R E, Jaffe J H, Fudala PJ. A controlled trial of buprenorphine: treatment for opioid dependence. JAMA 1992; 267: 2750–2755
   PubMed Web of Science ®Google Scholar
• Strain E C, Stitzer M L, Liebson IA. Buprenorphine vs. methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology 1994; 116: 401–406
   PubMed Web of Science ®Google Scholar
• Banys P, Clark H W, Tusel DJ. An open trial of low-dose buprenorphine in treating methadone withdrawal. J Subst Abuse Treat 1994; 11: 9–15
   PubMed Web of Science ®Google Scholar
• Strain E C, Preston K L, Liebson IA. Acute effects of buprenorphine, hydromorphone, and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 1992; 261: 985–993
   PubMed Web of Science ®Google Scholar
• Strain E C, Preston K L, Liebson IA. Buprenorphine effects in methadone-maintained volunteers. J Pharmacol Exp Ther 1995; 272: 628–638
   PubMed Web of Science ®Google Scholar
• Walsh S L, June H L, Schuh KJ. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 1995; 119: 268–276
   PubMed Web of Science ®Google Scholar
• Handelsman L, Cochrane K J, Aronson MJ. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13: 293–308
   PubMed Web of Science ®Google Scholar
• Milby J B, Hohmann A A, Gentile M. Methadone maintenance outcome as a function of detoxification phobia. Am J Psychiatry 1994; 151: 1031–1037
   Google Scholar
• Martin W R, Jasinski DR. Physiological parameters of morphine dependence in man: tolerance, early abstinence, protracted abstinence. J Psychiatr Res 1969; 7: 9–17
   PubMed Web of Science ®Google Scholar
• Martin W R, Jasinski D R, Haertzen CA. Methadone: a reevaluation. Arch Gen Psychiatry 1973; 28: 286–295
   PubMed Web of Science ®Google Scholar
• Gossop M, Battersby M, Strang J. Self-detoxification by opiate addicts: a preliminary investigation. Br J Psychiatry 1991; 159: 208–212
   PubMed Web of Science ®Google Scholar
• Sugerman A A, Miksztal M W, Freymuth HW. Comparison of prazepam and placebo in the treatment of convalescing narcotic addicts. J Clin Pharmacology 1971; 11: 383–387
   Google Scholar
• Brewer C, Rezae H, Bailey C. Opioid withdrawal and naltrexone induction in 48–72 hours with minimal drop-out using a modification of the naltrexone-clonidine technique. Br J Psychiatry 1988; 153: 340–343
   PubMed Web of Science ®Google Scholar
• O'Connor P G, Waugh M E, Schottenfeld RS. Ambulatory opiate detoxification and primary care: a role for the primary care physician. J Gen Intern Med 1992; 7: 532–534
   PubMedGoogle Scholar
• Preston K L, Bigelow G E, Liebson IA. Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification. Clin Pharmacol Ther 1985; 38: 219–227
   Google Scholar
• Gawin F H, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: clinical observations. Arch Gen Psychiatry 1986; 43: 107–113
   PubMed Web of Science ®Google Scholar
• Weddington W W, Brown B S, Haertzen CA. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts: a controlled residential study. Arch Gen Psychiatry 1990; 47: 861–868
   PubMed Web of Science ®Google Scholar
• Satel S L, Price L H, Palumbo JM. Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry 1991; 48: 1712–1716
   Google Scholar